At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 536 enrolled
Drug / intervention
LY2963016 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating LY2963016, Lantus, and 1 other intervention for Diabetes Mellitus, Type 1. Completed, enrolled 536 participants across 52 sites in 9 countries.
Detailed Summary
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesBelgium, Germany, Greece, Hungary, Japan, Mexico, Poland, Romania, United States
CollaboratorsBoehringer Ingelheim
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionAug 2012
Study CompletionApr 2013
TodayJul 2026
First PostedAug 22, 2011
Enrollment StartAug 1, 2011
Primary CompletionAug 1, 2012
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.9 years ago
Interventions
LY2963016drug
Administered subcutaneously
Lantusdrug
Administered subcutaneously
Insulin Lisprodrug
Administered subcutaneously